BACKGROUND: The occurrence of postoperative complications may have a significant negative impact on the prognosis of patients with gastrointestinal cancers. The inflammatory response releases systemic cytokines, which may induce residual cancer cell growth. Recently, neoadjuvant chemotherapy (NAC) was found to improve the prognosis of advanced gastric cancer (GC). We hypothesize that when postoperative complications occur after gastrectomy, NAC treatment of micrometastases can prevent residual cancer cell growth. METHODS: This study included 101 patients who underwent curative resection after NAC for GC from 2005 to 2015. Clinical data, including intraoperative parameters, were collected retrospectively. Overall survival (OS) and relapse-free survival (RFS) were compared between the patients with complications and those without complications. RESULTS: Of the 101 patients, 35 (34.7%) had grade 2 or higher complications. Among those with complications, the 3- and 5-year OS rates were 63.5 and 58.2% and the 3- and 5-year RFS rates 41.7 and 41.7%, respectively. Among those without complications, the 3- and 5-year OS rates were 65.9 and 56.3% and the 3- and 5-year RFS rates 51.1 and 43.9%, respectively. There was no significant difference in prognosis between the patients with complications and those without complications. CONCLUSION: Our study is the first to demonstrate the potential of NAC to abolish the poor prognosis induced by postoperative complications after curative resection for GC.
BACKGROUND: The occurrence of postoperative complications may have a significant negative impact on the prognosis of patients with gastrointestinal cancers. The inflammatory response releases systemic cytokines, which may induce residual cancer cell growth. Recently, neoadjuvant chemotherapy (NAC) was found to improve the prognosis of advanced gastric cancer (GC). We hypothesize that when postoperative complications occur after gastrectomy, NAC treatment of micrometastases can prevent residual cancer cell growth. METHODS: This study included 101 patients who underwent curative resection after NAC for GC from 2005 to 2015. Clinical data, including intraoperative parameters, were collected retrospectively. Overall survival (OS) and relapse-free survival (RFS) were compared between the patients with complications and those without complications. RESULTS: Of the 101 patients, 35 (34.7%) had grade 2 or higher complications. Among those with complications, the 3- and 5-year OS rates were 63.5 and 58.2% and the 3- and 5-year RFS rates 41.7 and 41.7%, respectively. Among those without complications, the 3- and 5-year OS rates were 65.9 and 56.3% and the 3- and 5-year RFS rates 51.1 and 43.9%, respectively. There was no significant difference in prognosis between the patients with complications and those without complications. CONCLUSION: Our study is the first to demonstrate the potential of NAC to abolish the poor prognosis induced by postoperative complications after curative resection for GC.
Authors: Avo Artinyan; Sonia T Orcutt; Daniel A Anaya; Peter Richardson; G John Chen; David H Berger Journal: Ann Surg Date: 2015-03 Impact factor: 12.969
Authors: Kenneth G Walker; Stephen W Bell; Matthew J F X Rickard; Daniel Mehanna; Owen F Dent; Pierre H Chapuis; E Leslie Bokey Journal: Ann Surg Date: 2004-08 Impact factor: 12.969
Authors: T Yoshikawa; M Sasako; S Yamamoto; T Sano; H Imamura; K Fujitani; H Oshita; S Ito; Y Kawashima; N Fukushima Journal: Br J Surg Date: 2009-09 Impact factor: 6.939
Authors: Silvia Salvans; Xavier Mayol; Sandra Alonso; Ramon Messeguer; Marta Pascual; Sergi Mojal; Luis Grande; Miguel Pera Journal: Ann Surg Date: 2014-11 Impact factor: 12.969
Authors: Toni Lerut; Johnny Moons; Willy Coosemans; Dirk Van Raemdonck; Paul De Leyn; Herbert Decaluwé; Georges Decker; Philippe Nafteux Journal: Ann Surg Date: 2009-11 Impact factor: 12.969
Authors: Peter M Rothwell; F Gerald R Fowkes; Jill F F Belch; Hisao Ogawa; Charles P Warlow; Tom W Meade Journal: Lancet Date: 2010-12-06 Impact factor: 79.321
Authors: Rhami Khorfan; Cary Jo R Schlick; Anthony D Yang; David D Odell; David J Bentrem; Ryan P Merkow Journal: J Gastrointest Surg Date: 2019-11-20 Impact factor: 3.452